Anavex Life Sciences CORP 8-K filings

Anavex Life Sciences has filed its definitive proxy statement and mailed a letter to stockholders, urging them to vote for its director nominees and highlighting its strategy and board refreshment plans.

Anavex Life Sciences announced plans to refresh its Board of Directors by nominating two new independent directors and urged stockholders to reject a control attempt by PVG Asset Management Corporation and Patrick S. Adams.

Anavex Life Sciences announced preliminary financial results for its second fiscal quarter ended March 31, 2026, alongside a strategic update focusing on its lead compound ANAVEX2-73 for CNS diseases.

Anavex Life Sciences Corp. has submitted a compliance plan to Nasdaq to regain listing compliance after failing to file its Q1 2026 financial report on time.

Anavex Life Sciences Corp. has scheduled its 2026 Annual Meeting for September 24, 2026, and established a July 10 deadline for stockholder proposals.

Anavex Life Sciences has received a Nasdaq delinquency notice due to a delay in filing its Form 10-Q for the quarter ended March 31, 2026.

Anavex Life Sciences Corp. announces the departure of Chief Operating Officer Felix Lauscher following a corporate reorganization.

Anavex Life Sciences terminates CEO Christopher Missling for cause and appoints Terrie Kellmeyer as interim CEO, while also announcing a delay in its Q1 2026 10-Q filing.

Anavex Life Sciences Corp. has withdrawn its application for marketing authorization of blarcamesine in the EU for early Alzheimer's disease following negative feedback from the European Medicines Agency.

Anavex Life Sciences Corp. announced the appointment of Dr. Axel Paeger, a seasoned healthcare leader, to its Board of Directors, effective February 23, 2026.

Anavex Life Sciences reported improved first-quarter fiscal 2026 financial results with increased cash and reduced net loss, while advancing its clinical pipeline for neurological disorders.

Anavex Life Sciences reported its fiscal 2025 fourth-quarter financial results, highlighted by a reduced net loss, extended cash runway, and positive Phase 2 schizophrenia trial data, despite a negative EU regulatory trend vote for blarcamesine in Alzheimer's.

Anavex Life Sciences received a negative trend vote from the European Medicines Agency's CHMP for its blarcamesine Alzheimer's drug, but plans to request a re-examination while the FDA advises a meeting to discuss trial results.

Anavex Life Sciences Corp. has entered into a Sales Agreement with TD Securities (USA) LLC to offer and sell up to $150 million in common stock through an at-the-market offering.

Anavex Life Sciences Corp. announced the extension of its CEO's employment agreement through 2028 with a salary increase, and an indefinite term for its Principal Financial Officer's agreement with enhanced severance.

Anavex Life Sciences Corp. announced that its stockholders approved an amendment to the 2022 Omnibus Incentive Plan, re-elected all six director nominees, and ratified Grant Thornton LLP as its independent auditor at the Annual Meeting held on June 10, 2025.

Anavex Life Sciences Corp. has terminated its Amended and Restated Sales Agreement for an at-the-market offering program, effective July 24, 2024.

Anavex Life Sciences Corp. held its annual meeting on June 18, 2024, where shareholders elected six directors, ratified the company's auditor, and voted on executive compensation and a shareholder proposal.

Anavex Life Sciences announced its fiscal second quarter 2024 financial results, highlighting progress in its clinical programs and a strong cash position.